Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Angiogenesis, or new blood vessel formation, is known to be an important part of the malignant phenotype in most cancers, including breast cancer. Recent years have seen the discovery of many regulators of the angiogenic process. Foremost among these is vascular endothelial growth factor (VEGF), the ligand for a family of specific transmembrane receptors that regulate the angiogenic process. This article describes the role of VEGF and its receptors in angiogenesis (both physiologic and pathologic), and describes efforts to target VEGF and its receptor. It discusses the outcome of some early trials involving VEGF-targeting agents, and reviews future therapeutic trials involving VEGF in breast cancer.
Sledge
George W
GW
Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN 46260, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000502:physiology*; D005260:Female; D006801:Humans; D008222:Lymphokines / Q000037:antagonists & inhibitors* / Q000502:physiology*; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000517:prevention & control; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor